Bioqual, Inc. Share Price Other OTC
Equities
BIOQ
US09065J1016
Biotechnology & Medical Research
Sales 2022 | 66.15M 5.28B | Sales 2023 | 62.66M 5B | Capitalization | 67.98M 5.42B |
---|---|---|---|---|---|
Net income 2022 | 5M 399M | Net income 2023 | - 0 | EV / Sales 2022 | 1.2 x |
Net Debt 2022 | 16.54M 1.32B | Net Debt 2023 | 11.33M 904M | EV / Sales 2023 | 1.27 x |
P/E ratio 2022 |
11.9
x | P/E ratio 2023 |
81.7
x | Employees | - |
Yield 2022 |
1.43% | Yield 2023 |
0.66% | Free-Float | 55.92% |
Managers | Title | Age | Since |
---|---|---|---|
Mark G. Lewis
CEO | Chief Executive Officer | 69 | 31/07/03 |
Charles C Kirk
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 08/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 87 | 31/12/14 | |
Mark G. Lewis
CEO | Chief Executive Officer | 69 | 31/07/03 |
Director/Board Member | - | - |
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |